Innogenetics NV to distribute genetic testing products in Europe for Third Wave Technologies Inc.
Madison (Wisconsin, USA) and Gent (Belgium). Third Wave Technologies Inc. and Innogenetics NV announced that they have signed a four-year marketing and distribution agreement. Under the terms of the agreement, Third Wave has granted Innogenetics the exclusive European marketing and distribution rights for select Invader® molecular diagnostic products in the field of genetic testing.
The agreement will allow Third Wave to initiate its market penetration into the growing European molecular diagnostics market. Innogenetics' European-wide sales organization will market and distribute a number of Invader® clinical molecular diagnostic products for the genetic testing of risk factors in the areas of cardiovascular diseases, blood coagulation, and hearing disorders, including Factor V (Leiden), Factor II (Prothrombin), Connexin 26, and others.
These products are based on Third Wave's proprietary Invader® platform, a chemistry-based technology that provides exceptional accuracy, flexibility, and ease of use. Innogenetics may also distribute other new genetics-related tests developed by Third Wave in the future.
Under the agreement, Innogenetics will make minimum payments to Third Wave during the agreement's term.
"This marketing and distribution partnership represents a major milestone and is a great fit for both companies," said John J. Puisis, President and Chief Operating Officer of Third Wave. "Innogenetics has a proven track record in forging new markets and selling innovative molecular diagnostics to European clinical laboratories. Many of these customers have been requesting our Invader® products, and Innogenetics now will provide us with the avenue to this important market."
"Innogenetics is very pleased to be the European distributor for Third Wave's genetic product menu," said Philippe Archinard, Chief Executive Officer of Innogenetics. "Coupling the strength of our established European sales and marketing team with state-of-the-art Invader® products is a compelling proposition for both organizations and our European customers. We are excited by this new opportunity to extend and consolidate our genetic testing portfolio and sales revenue lines."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
